Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of pertuzumab in patients from prior Roche-sponsored pertuzumab trials
2014-002048-42Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pertuzumab in Nonhematologic neoplasms and breast cancer, sponsored by Roche. Primary endpoint: Incidence of adverse events. Started Oct 2014; status: completed.
02
Drugs
pertuzumab
03
Conditions
Nonhematologic neoplasmsbreast cancer
Beyond the preview
Go deeper on 2014-002048-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002048-42.